Three competitive National Cancer Institute grants totaling $13.5 million will support the Roswell Park Comprehensive Cancer Center team leading a multi-institutional effort aimed at improving the potential of immune checkpoint inhibitors, in close collaboration with experts from the University of Rochester’s Wilmot Cancer Institute and Kaiser Permanente Northern California Division of Research.

A phase 1 clinical trial conducted exclusively at Roswell Park shows that a novel treatment regimen can make immunotherapy more effective in patients with metastatic triple-negative breast cancer (mTNBC). Results of the study are reported in The Journal for ImmunoTherapy of Cancer.

Offering access to comprehensive dermatology and treatment of benign disease, the Roswell Park Care Network welcomes physician and longtime faculty member Marcelle Grassi, MD, and her Cheektowaga practice as its newest location.

Research led by Roswell Park Comprehensive Cancer Center and Genome Protection Inc. has detected activity in the “dark genome” that could help transform the diagnosis and treatment of five of the 10 most deadly cancers in the U.S.

Roswell Park Comprehensive Cancer Center and Generate:Biomedicines announce a strategic collaboration to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors. In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.